What's new

Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive

Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive

Jun 5, 2025 - 15:00
 0
Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive
Orphan designation: posnafusp alfa Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome), 14/01/2022 Positive
Read More

Tags:

Previous Article

Orphan designation: human decorin fused to the truncated homing peptide CRK Trea...

Next Article

Orphan designation: autologous T lymphocyte-enriched population of cells transdu...

Related Posts

EMEA-003542-PIP01-23

EMEA-003542-PIP01-23

Jun 10, 2025  0

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 11, 2025  0

Human medicines European public assessment report (EPAR): Ztalmy, ganaxolone, Date of authorisation: 26/07/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 2, 2025  0